Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) Research & Development (2016 - 2025)

Biomerica's Research & Development history spans 16 years, with the latest figure at $193000.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 24.9% year-over-year to $193000.0; the TTM value through Nov 2025 reached $874000.0, down 24.72%, while the annual FY2025 figure was $1.0 million, 31.39% down from the prior year.
  • Research & Development for Q4 2025 was $193000.0 at Biomerica, down from $212000.0 in the prior quarter.
  • Across five years, Research & Development topped out at $564000.0 in Q1 2021 and bottomed at $193000.0 in Q4 2025.
  • The 5-year median for Research & Development is $369344.0 (2021), against an average of $362434.4.
  • The largest annual shift saw Research & Development plummeted 46.38% in 2021 before it surged 33.99% in 2022.
  • A 5-year view of Research & Development shows it stood at $548000.0 in 2021, then fell by 15.69% to $462000.0 in 2022, then fell by 10.82% to $412000.0 in 2023, then crashed by 37.62% to $257000.0 in 2024, then decreased by 24.9% to $193000.0 in 2025.
  • Per Business Quant, the three most recent readings for BMRA's Research & Development are $193000.0 (Q4 2025), $212000.0 (Q3 2025), and $252000.0 (Q2 2025).